MedTrace Logo

A Registry of Patients With Moderate to Severe Plaque Psoriasis

NCT02786186 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2376

Last updated 2026-02-19

No results posted yet for this study

Summary

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.

Conditions

Interventions

DRUG

Secikinumab

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-23
Primary Completion
2026-01-22
Completion
2026-01-22
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786186 on ClinicalTrials.gov